A guide on using Dulaglutide for T2D
Date Published:
Wednesday, September 8, 2021
Duration:
31:45
Dr Rinki Murphy discusses type 2 diabetes management with a focus on GLP- 1 receptor agonists. We discuss the indications for use and how to use dulaglutide now that it has medsafe approval.
Topics:
- 01:32 Lifestyle interventions and weight reduction
- 04:27 how do we best approach pharmacological management?
- 06:52 GLP-1 receptor agonists. How do these medication work exactly?
- 08:35 advantages of these medications in the diabetic patient.
- 10:00 What cohort will benefit from these medications?
- 11:16 benefits beyond diabetes
- 12:15 When should we be cautious about prescribing these medications?
- 12:59 Do we have to worry about hypoglycemia?
- 13:56 How do these new medications fit in our prescribing pathway for diabetes?
- 16:43 What GLP-1 receptor agonists are currently available in NZ?
- 17:45 Why would we choose Trulicity over another GLP-1 receptor agonist?
- 19:26 Who is it funded for?
- 21:18 Dosing titration and monitoring
- 28:18 What are the common side effects?
- 19:14 Weigth loss
- 30:00 Take-home messages
Take-home messages
|
Resources
- Best Practice e-Journal - Diabetes Special Edition bpacnz (2021)
- Trulicity (dulaglutide 1.5 mg/0.5 mL) solution for injection NZ Data Sheet (2021)
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (2019)
- Dulaglutide for type 2 diabetes. Aust Prescr (2018)
- Type 2 Diabetes Management Guidance. NZSSD and MOH (2021)
- Decision to fund two new medicines for type 2 diabetes - Amended with Q&A PHARMAC (2021)
Presenter
Rinki Murphy
Diabetes Physician
Rinki is an Associate Professor in Medicine at the University of Auckland and Principle investigator at the Maurice Wilkins Centre for Biodiscovery. She is a diabetologist at Auckland and Counties Manukau DHBs.
This webinar is supported by Lilly:
This presentation is intended for qualified health practitioners professional development and should not be relied upon for any other purpose. Any opinions offered are those of the presenter or other speaker and do not necessarily represent the views of Goodfellow Unit.